B. Demediuk
St. Vincent's Health System
15 Papers
93 Citations
B. Demediuk is an academic researcher from St. Vincent's Health System. The author has contributed to research in topics: Hepatitis B & Hepatitis B virus. The author has an hindex of 5, co-authored 12 publications. Previous affiliations of B. Demediuk include University of Melbourne.
Chat about Author
Papers
Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors.
Alexander J. Thompson,Anna Ayres,Lilly Yuen,Angeline Ingrid Bartholomeusz,D. Scott Bowden,David Iser,Robert Y M Chen,B. Demediuk,Gideon Shaw,Sally Bell,Katrina J R Watson,Stephen Locarnini,Paul V. Desmond +12 more
TL;DR: In this paper, a Cox proportional hazards model was used to determine variables independently predicting for the early onset of lamivudine resistance, with rate ratios of 4.93 (95% confidence interval [CI]: 1.32-18.5, P < 0.05).
48
Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients
Sally Bell,A. Lau,Alexander J. Thompson,Katrina J R Watson,B. Demediuk,Gideon Shaw,Robert Y M Chen,Anna Ayres,Lilly Yuen,Angeline Ingrid Bartholomeusz,Stephen Locarnini,Paul V. Desmond +11 more
TL;DR: Two thirds of this cohort had active replication and were at increased risk of developing cirrhosis and/or hepatoma, and Screening should be offered to people born in, or with parents born in areas of high endemnicity.
34
Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience.
Grace C Lovett,Tin Nguyen,David Iser,Jacinta A Holmes,Robert Chen,B. Demediuk,Gideon Shaw,Sally Bell,Paul V. Desmond,Alexander J. Thompson +9 more
TL;DR: Tenofovir is an efficacious, safe and well-tolerated treatment in an Australian real-world tertiary care setting and three episodes of virological breakthrough occurred in the setting of non-compliance.
G80S-linked ferroportin disease: classical ferroportin disease in an Asian family and reclassification of the mutant as iron transport defective.
Cameron J. McDonald,Daniel F. Wallace,L. Ostini,Sally Bell,B. Demediuk,V. Nathan Subramaniam,V. Nathan Subramaniam +6 more
TL;DR: The G80S mutation results in a mutated ferroportin associated with iron overload and is predicted to be defective in iron export.
22
Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age.
Jessica Howell,David A. Anderson,Stephen Bloom,John S Lubel,John S Lubel,William Kemp,William Kemp,James Williams,Sally Bell,C. Croagh,B. Demediuk,Paul V. Desmond,Paul V. Desmond,S Hall,S Hall,Jacinta A Holmes,Thai Hong,David Iser,Lucy Lim,Timothy Papaluca,Timothy Papaluca,Marno Ryan,Kumar Visvanathan,Kumar Visvanathan,Yinzong Xiao,Yinzong Xiao,Yinzong Xiao,Caroline van Gemert,Margaret Hellard,Margaret Hellard,Margaret Hellard,Alexander J. Thompson,Alexander J. Thompson +32 more
9